Literature DB >> 24690026

Doctors' compliance with national guidelines and clinical pathway on the treatment of tuberculosis inpatients in Hubei, China.

Xiaofei Zheng1, Fangying Zhong, Xinping Zhang.   

Abstract

RATIONALE, AIMS AND
OBJECTIVES: The Ministry of Health in China has enacted a revised National Tuberculosis Control Program (NTP) guidelines and clinical pathway (CP) on new smear-positive pulmonary tuberculosis (TB) inpatients to improve the quality of TB care and asked doctors' compliance to them on the treatment of TB inpatients. However, it remains unknown whether doctors adhere to them well. So this study focuses on evaluating the doctors' compliance with them in one representative TB hospital for medical quality improvement.
METHODS: A hospital-based retrospective study involving all medical records of newly diagnosed smear-positive pulmonary TB inpatients from July 2011 to July 2013. Analysis indicators including adequate drug regimens rate, adequate drug dosages rate and adequate length of hospital stay rate were chosen to assess doctors' compliance with NTP guidelines and CP on the treatment of new smear-positive pulmonary TB inpatients. The optimal value of these indicators is 100%.
RESULTS: Of the 334 inpatients selected, the rate of adequate drug regimens prescribed is 26.95% (90/334), and the rate of adequate drug dosages is 0% (0/90). For the dosage of single drug, the rates of adequate dosage of isoniazid, rifampicin, pyrazinamide and ethambutol are 24.44% (22/90), 85.56% (77/90), 70% (63/90) and 13.33% (12/90). Moreover, 75.56% (68/90) of isoniazid was prescribed too high and 83.34% (75/90) of ethambutol was prescribed too low. The rate of adequate length of hospital stay provided is 28.44% (95/334).
CONCLUSION: Doctors' compliance with NTP guidelines and CP on new smear-positive pulmonary TB inpatients is depressed and needs improvement.
© 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  compliance; doctors; drug dosages; drug regimens; length of hospital stay; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24690026     DOI: 10.1111/jep.12127

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  3 in total

1.  The perceived and objectively measured effects of clinical pathways' implementation on medical care in China.

Authors:  Jie Bai; Fei Bai; Hongbo Zhu; Di Xue
Journal:  PLoS One       Date:  2018-05-07       Impact factor: 3.240

2.  Relationship between physician financial incentives and clinical pathway compliance: a cross-sectional study of 18 public hospitals in China.

Authors:  Jie Bai; Kate Bundorf; Fei Bai; Huiqin Tang; Di Xue
Journal:  BMJ Open       Date:  2019-05-28       Impact factor: 2.692

3.  Over- and under-treatment of TB patients in Eastern China: an analysis based on health insurance claims data.

Authors:  Wenhui Mao; Weixi Jiang; Carol Hamilton; Hui Zhang; Fei Huang; Henry Lucas; Shitong Huan; Shenglan Tang
Journal:  Trop Med Int Health       Date:  2019-07-29       Impact factor: 2.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.